CliffBio
small molecule

SYPRINE

TRIENTINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyBAUSCH HEALTH AMERICAS INC

Drug detail

Brand nameSYPRINE
Active ingredientTRIENTINE HYDROCHLORIDE
Strength250MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 1985
Marketing statusRX

More from BAUSCH HEALTH AMERICAS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SYPRINE patent cliff — loss of exclusivity — | CliffBio